Clinical trial
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced Gastrointestinal Stromal Tumors: a Randomized, Open, Controlled, Single-center Clinical Study
NCT05751733 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced Gastrointestinal Stromal Tumors: a Randomized, Open, Controlled, Single-center Clinical Study
- Lead sponsor
- Xiangya Hospital of Central South University
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- February 1, 2023
- Completion date
- January 1, 2027
- Enrollment
- 258 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.